Leiomyosarcoma of prostate: Case report and literature review

Zazzara, Michele; Divenuto, L.; Scarcia, Marcello; Cardo, Giuseppe; Maselli, Federica; Ludovico, Giuseppe Mario

doi:10.1016/j.eucr.2017.11.024

Cited by 16 publications

(21 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[2,10,11] The 5-year survival of prostatic leiomyosarcoma is very poor, ranging from 0% to 60%. [2,3] The prognosis for prostatic leiomyosarcomas is often poor. Survival is very variable according to the series, it is on average less than 10% at 5 years [11].…”

Section: Discussionmentioning

confidence: 99%

“…It is the most common primary sarcoma of the prostate in adults and comprises 38% to 52% of primary prostate sarcomas [2]. It has a more aggressive clinical course compared to prostatic adenocarcinoma [3]. Its diagnosis is generally made at a late stage, because of the clinical and radiological non-specificity.…”

Section: Introductionmentioning

confidence: 99%

“…It is often bulky beyond the prostate gland and invading neighboring organs. His prognosis remains very grim [3].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Leiomyosarcoma of Prostate: A Case Report and Literature Review

Heddat¹,

Houry²,

Rabii³

2020

Health Sci

View full text Add to dashboard Cite

Prostate leiomyosarcoma is an extremely rare and very aggressive neoplasm that represents less than 0.1% of primary malignant tumors of the prostate. We present a patient with primary leiomyosarcoma of prostate and examine the cases reported in the literature to discuss the clinical, diagnostic and therapeutic aspects of this rare tumor. Median survival was estimated at 17 months (95% CI 20.7–43.7 months) and the actuarial survival rates at 1, 3 and 5 years were 68%, 34% and 26%, respectively. The only predictors of long-term survival were negative surgical margins and the absence of metastatic disease at presentation. A multidisciplinary approach is necessary for the proper management of this terrible entity. Surgery with or without chemotherapy seems to be the main therapeutic method for operable leimyosarcomas, but in general there is no consensus on the best therapeutic approach. Most cases are diagnosed at an advanced stage of the disease. A global multicenter trial is needed to find therapies that would improve the prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Leiomyosarcoma of Prostate: A Case Report and Literature Review

Heddat¹,

Houry²,

Rabii³

2020

Health Sci

View full text Add to dashboard Cite

show abstract

“…Neoplasic cells commonly express vimentin and α-SMA, whereas cytokeratin, desmin and S-100 protein are expressed in rare cases, while CD117, CD34 and CD99 are negative in the majority of cases [ 2 , 3 ].…”

Section: Clinical Discussionmentioning

confidence: 99%

“…[ 1 ]. It is the most common primary sarcoma of the prostate in adults accounting for 38%–52% [ 2 ]. The presentation came with non-specific signs and symptoms likewise other forms of prostatic pathology like benign prostatic hyperplasia [ 3 ].…”

Section: Introduction and Importancementioning

confidence: 99%

Recurrent hematuria: A rare presentation of leiomyosarcoma of the prostate

Loghmari

Othmane

Belkacem

et al. 2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Analysis of three primary prostatic sarcoma cases and literature review

Wei,

Wang,

Xie

et al. 2024

The Prostate

View full text Add to dashboard Cite

ObjectiveThe objective of this study is to evaluate the clinical presentations, diagnostic approaches, and treatment modalities for primary prostate sarcoma postradical prostatectomy, aiming to enhance its diagnosis and management.MethodsWe retrospectively reviewed the clinical records of three male patients diagnosed with primary prostate sarcoma at Beijing Chaoyang Hospital, affiliated with Capital Medical University, from February 2014 to February 2024. All patients underwent transrectal prostate biopsies, which informed the decision to proceed with laparoscopic radical prostatectomies. After surgery, one patient received a combination of epirubicin and ifosfamide as immunotherapy, along with external beam radiotherapy. After comprehensive discussions regarding potential benefits and risks, the remaining two patients decided against undergoing radiotherapy and chemotherapy.ResultsBased on the pathological examination results, two patients were diagnosed with stromal sarcoma and one with spindle cell sarcoma, all classified as high‐grade sarcomas. Immunohistochemical analysis showed that all three cases were positive for VIMENTIN, but other results did not show significant specificity. During the follow‐up period, one patient died within 12 months, and two patients were lost to follow‐up after 6 months. However, there were no evident signs of recurrence observed during the follow‐up period.ConclusionsPrimary prostate sarcoma is extremely rare and typically has a poor prognosis once diagnosed. Early diagnosis should be based on pathological and immunohistochemical testing results, followed by prompt surgical treatment and adjuvant radiotherapy and chemotherapy. Despite these measures, recurrence is common, underscoring the need for a detailed and appropriate treatment plan and systematic therapy for affected patients.

show abstract

Leiomyosarcoma of prostate: Case report and literature review

Cited by 16 publications

References 5 publications

Leiomyosarcoma of Prostate: A Case Report and Literature Review

Leiomyosarcoma of Prostate: A Case Report and Literature Review

Recurrent hematuria: A rare presentation of leiomyosarcoma of the prostate

Analysis of three primary prostatic sarcoma cases and literature review

Contact Info

Product

Resources

About